bioMérieux Improves Food Safety Testing Workflow with VIDAS® Heat and Go
05 Dicembre, 2007
bioMérieux Launches VIDAS® NT-proBNP, an Aid for Diagnosis and Prognosis of Heart Failure
01 Ottobre, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics.
Early Diagnosis of Sepsis: bioMérieux presents new Sepsis Handbook at International Sepsis Forum
26 Settembre, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of the “Sepsis Handbook”. This comprehensive book, produced by bioMérieux Editions, will be presented in a special preview at the International Sepsis Forum (ISF) held in Paris (Institut Pasteur), September 26-29, 2007.
bioMérieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment
17 Settembre, 2007
bioMérieux and Ipsen announce today that they have signed an agreement by which bioMérieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMérieux and Ipsen.
bioMérieux launches the first automated detection test for Clostridium difficile A and B toxins
24 Luglio, 2007
A new, rapid, and effective solution in the fight against hospital-acquired (nosocomial)infections. bioMérieux, a world leader in the field of in vitro diagnostics, (Euronext : BIM) has just launched VIDAS® C. difficile Toxin A&B, a test for the detection of a bacterium responsible for fatal nosocomial epidemics in Canada, the United States and, more recently, in Europe.
